Cargando…

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs

A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to assess 3HP-mediated clearance of M. tuberculosis bacteria in macaques with asymptomatic LTBI. Twelve Indian-origin rhes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharan, Riti, Ganatra, Shashank R., Singh, Dhiraj K., Cole, Journey, Foreman, Taylor W., Thippeshappa, Rajesh, Peloquin, Charles A., Shivanna, Vinay, Gonzalez, Olga, Day, Cheryl L., Gandhi, Neel R., Dick, Edward J., Hall-Ursone, Shannan, Mehra, Smriti, Schlesinger, Larry S., Rengarajan, Jyothi, Kaushal, Deepak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479578/ https://www.ncbi.nlm.nih.gov/pubmed/35862216 http://dx.doi.org/10.1172/JCI161564

Ejemplares similares

Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model
por: Sharan, Riti, et al.
Publicado: (2022)

Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy
por: Singh, Bindu, et al.
Publicado: (2023)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Characterizing Early T Cell Responses in Nonhuman Primate Model of Tuberculosis
por: Sharan, Riti, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas
por: Singh, Bindu, et al.
Publicado: (2021)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection
por: Gough, Maya, et al.
Publicado: (2022)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Toward a Macaque Model of HIV-1 Infection: Roadblocks, Progress, and Future Strategies
por: Thippeshappa, Rajesh, et al.
Publicado: (2020)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Peripheral Blood Markers Correlate with the Progression of Active Tuberculosis Relative to Latent Control of Mycobacterium tuberculosis Infection in Macaques
por: Gough, Maya, et al.
Publicado: (2022)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
por: Singh, Dhiraj, et al.
Publicado: (2021)

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets
por: Singh, Dhiraj Kumar, et al.
Publicado: (2020)

Author Correction: Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets
por: Singh, Dhiraj Kumar, et al.
Publicado: (2021)

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
por: Juarez-Reyes, Maria, et al.
Publicado: (2016)

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study
por: Lam, Chee Kin, et al.
Publicado: (2018)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
por: Yu, Ya-Yen, et al.
Publicado: (2019)

Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
por: Singh, Dhiraj K., et al.
Publicado: (2022)

Immune Responses in Lung Granulomas during Mtb/HIV Co-Infection: Implications for Pathogenesis and Therapy
por: Kaushal, Deepak, et al.
Publicado: (2023)

Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis — Colorado, 2011–2012
por: Bargman, Carolyn, et al.
Publicado: (2013)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study
por: Yang, Heng, et al.
Publicado: (2021)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
por: Rosenthal, Ian M, et al.
Publicado: (2007)

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
por: Alvarez, G. G., et al.
Publicado: (2020)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

Macaques as model hosts for studies of HIV-1 infection
por: Misra, Anisha, et al.
Publicado: (2013)

Transcriptional Reprogramming in Nonhuman Primate (Rhesus Macaque) Tuberculosis Granulomas
por: Mehra, Smriti, et al.
Publicado: (2010)

Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models
por: Choudhary, Shambhunath, et al.
Publicado: (2022)

Breaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives
por: Thippeshappa, Rajesh, et al.
Publicado: (2012)

Improved Xenobiotic Metabolism and Reduced Susceptibility to Cancer in Gluten-Sensitive Macaques upon Introduction of a Gluten-Free Diet
por: Sestak, Karol, et al.
Publicado: (2011)

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
por: Pease, Christopher, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bq0pn24m020lopvshfodpoljfl